Exelixis, Inc. is a biopharmaceutical company, which engages in the developing and commercializing small molecule therapies for the treatment of cancer. Its brands include COMETRIQ and cobimetinib. The company focuses on their proprietary resources and development and commercialization of cabozantinib. Exelixis was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.
Put trades that are bought on or above the market's asking price OR call trades that are sold on or less than the market's bid price - expecting a move to the downside.